Novel insights into the effect of Xiaoyao san on corticosterone-induced hepatic steatosis: inhibition of glucocorticoid receptor/perilipin-2 signaling pathway

Abstract

Objective: Xiaoyao san (XYS) is a classic traditional Chinese medicinal formula. It has been clinically administered to regulate liver function. However, its mechanisms in glucocorticoid-induced hepatic steatosis are unknown. This study aimed to investigate whether XYS protects against corticosterone (CORT)-induced hepatic steatosis, and to explore its mechanism.Methods: High-fat diet mice induced with hepatic steatosis by 2 mg/kg CORT were administered 2.56 g/kg or 5.12 g/kg XYS daily for 7 weeks. The effects of XYS on hepatic steatosis in mice were evaluated by H&E and Oil Red O staining and by measuring their plasma lipids (triglyceride, total cholesterol, and free fatty acids). The mechanism of XYS against hepatic steatosis was investigated by network pharmacology, immunohistochemistry, western blotting, and gain-of-function/loss-of-function experiments. Results: XYS alleviated CORT-induced steatosis, decreased plasma lipids, and inhibited glucocorticoid receptor (GR) activation in the liver. Network pharmacology data indicated that XYS may have mitigated hepatic steatosis via GR which mediated adipose differentiation-related protein (ADFP). Gain-of-function/loss-of-function experiments in vitro confirmed that GR positively regulated ADFP expression. Conclusions: XYS ameliorated CORT-induced hepatic steatosis by downregulating the GR/ADFP axis and inhibiting lipid metabolism. Our studies implicate that XYS is promising as a therapy for CORT-induced hepatic steatosis, and lay the foundation for designing novel prophylactic and therapeutic strategies on CORT-induced hepatic steatosis.

Keywords

Adipose differentiation-related protein / Glucocorticoid receptor / Hepatic steatosis / Network pharmacology / Xiaoyao san

References

[[1]] Younossi Z, Anstee QM, Marietti M, et al.Global burden of nafld and nash: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15(1):11-20.

[[2]] Chalasani N, Younossi Z, Lavine JE, et al.The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology (Baltimore MD) 2018;67(1): 328-357.

[[3]] Sheka AC, Adeyi O, Thompson J, et al.Nonalcoholic steatohepatitis: a review. JAMA 2020;323(12):1175-1183.

[[4]] Tarantino G, Finelli C.Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease. World J Gastroenterol 2013;19(40):6735-6743.

[[5]] Rockall AG, Sohaib SA, Evans D, et al.Hepatic steatosis in Cushing’s syndrome: a radiological assessment using computed tomography. Eur J Endocrinol 2003;149(6):543-548.

[[6]] Jung UJ, Choi MS.Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 2014;15(4):6184-6223.

[[7]] Fardet L, Kassar A, Cabane J, et al.Corticosteroid-induced adverse events in adults: frequency, screening and prevention. Drug Saf 2007;30(10):861-881.

[[8]] Pasquali R, Vicennati V, Cacciari M, et al.The hypothalamicpituitary- adrenal axis activity in obesity and the metabolic syndrome. Ann N Y Acad Sci 2010;1083(1):111-128.

[[9]] Liu YZ, Wang YX, Jiang CL.Inflammation: the common pathway of stress-related diseases. Front Human Neurosci 2017;11:316.

[[10]] Fries GR, Gassen NC, Rein T.The fkbp51 glucocorticoid receptor co-chaperone: regulation, function, and implications in health and disease. Int J Mol Sci 2017;18(12):2614.

[[11]] Marino JS, Stechschulte LA, Stec DE, et al.Glucocorticoid receptor b induces hepatic steatosis by augmenting inflammation and inhibition of the peroxisome proliferator-activated receptor (ppar) a. J Biol Chem 2016;291(50):25776-25788.

[[12]] Kaushik S, Cuervo AM.Degradation of lipid droplet-associated proteins by chaperone-mediated autophagy facilitates lipolysis. Nat Cell Biol 2015;17(6):759-770.

[[13]] Day CP.Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int 2006;26(9):1021-1028.

[[14]] Angulo P.Nonalcoholic fatty liver disease.NEngl J Med 2002;346(16):1221-1231.

[[15]] Greuter T, Malhi H, Gores GJ, et al.Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. JCI Insight 2017;2(17):e95354.

[[16]] Feiteiro J, Mariana M, Verde I, et al.Genomic and nongenomic effects of mifepristone at the cardiovascular level: a review. Reprod Sci 2017;24(7):976-988.

[[17]] Wang M, Huang W, Gao T, et al.Effects of xiao yao san on interferon-a-induced depression in mice. Brain Res Bull 2018;139: 197-202.

[[18]] Zheng X, Cheng Y, Chen Y, et al.Ferulic acid improves depressivelike behavior in prenatally-stressed offspring rats via antiinflammatory activity and HPA axis. Int J Mol Sci 2019;20(3):493.

[[19]] Wei Z, Wang J, Shi M, et al.Saikosaponin A inhibits LPS-induced inflammatory response by inducing liver x receptor alpha activation in primary mouse macrophages. Oncotarget 2016;7(31):48995-49007.

[[20]] Xie T, Li K, Gong X, et al.Paeoniflorin protects against liver ischemia/reperfusion injury in mice via inhibiting HMGB1-TLR4 signaling pathway. Phytother Res 2018;32(11):2247-2255.

[[21]] Jung JC, Lee YH, Kim SH, et al.Hepatoprotective effect of licorice, the root of Glycyrrhiza uralensis Fischer, in alcohol-induced fatty liver disease. BMC Complement Altern Med 2016;16:19.

[[22]] Huo X, Yang S, Sun X, et al.Protective effect of glycyrrhizic acid on alcoholic liver injury in rats by modulating lipid metabolism. Molecules (Basel, Switzerland) 2018;23(7):1623.

[[23]] Orazizadeh M, Fakhredini F, Mansouri E, et al.Effect of glycyrrhizic acid on titanium dioxide nanoparticles-induced hepatotoxicity in rats. Chem Biol Interact 2014;220:214-221.

[[24]] Luo HG, Chen JX, Zhang Q, et al.Comparative study on effects of xiaoyao powder and its modified prescription on plasma metabolomics of rats with chronic immobilization stress. Chin J Integr Med 2013;19(8):610-615.

[[25]] Gao XX, Cui J, Zheng XY, et al.An investigation of the antidepressant action of xiaoyaosan in rats using ultra performance liquid chromatography-mass spectrometry combined with metabo- nomics. Phytother Res 2013;27(7):1074-1085.

[[26]] Yoh T, Nakashima T, Sumida Y, et al.Effects of glycyrrhizin on glucocorticoid signaling pathway in hepatocytes. Dig Dis Sci 2002;47(8):1775-1781.

[[27]] Li ZY, Jiang YM, Liu YM, et al.Saikosaponin D acts against corticosterone-induced apoptosis via regulation of mitochondrial GR translocation and a GR-dependent pathway. Prog Neuropsycho- pharmacol Biol Psychiatry 2014;53:80-89.

[[28]] Zhang H, Chen S, Qin F, et al.Simultaneous determination of 12 chemical constituents in the traditional Chinese medicinal prescriptionXiao- Yao-San-Jia-WeibyHPLCcoupledwithphotodiodearray detection. J Pharm Biomed Anal 2008;48(5):1462-1466.

[[29]] Zhang L, Dasuri K, Fernandez-Kim SO, et al.Adipose-specific ablation of Nrf2 transiently delayed high-fat diet-induced obesity by altering glucose, lipid and energy metabolism of male mice. Am J Transl Res 2016;8(12):5309-5319.

[[30]] Jung HY, Kim B, Ryu HG, et al.Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice. Diabetes Obes Metab 2018;20(7):1688-1701.

[[31]] Woods CP, Hazlehurst JM, Tomlinson JW.Glucocorticoids and non-alcoholic fatty liver disease. J Steroid Biochem Mol Biol 2015;154:94-103.

[[32]] D’Souza AM, Beaudry JL, Szigiato AA, et al. Consumption of a high-fat diet rapidly exacerbates the development of fatty liver disease that occurs with chronically elevated glucocorticoids. Am J Physiol Gastrointest Liver Physiol 2012;302(8):G850-G863.

[[33]] Ding F, Wu J, Liu C, et al.Effect of xiaoyaosan on colon morphology and intestinal permeability in rats with chronic unpredictable mild stress. Front Pharmacol 2020;11:1069.

[[34]] Li P, Tang XD, Cai ZX, et al.Cnp signal pathway up-regulated in rectum of depressed rats and the interventional effect of xiaoyaosan. World J Gastroenterol 2015;21(5):1518-1530.

[[35]] Kuo T, Chen TC, Lee RA, et al.Pik3r1 is required for glucocorticoid-induced perilipin 1 phosphorylation in lipid droplet for adipocyte lipolysis. Diabetes 2017;66(6):1601-1610.

[[36]] Blouin CM, LeLay S,Eberl A, et al. Lipiddropletanalysis incaveolindeficientadipocytes: alterations in surfacephospholipidcomposition and maturation defects. J Lipid Res 2010;51(5):945-956.

[[37]] Livak KJ, Schmittgen TD.Analysis of relative gene expression data using real-time quantitative pcr and the 2(-Delta Delta C(T)) method. Methods 2001;25(4):402-408.

[[38]] Ji E, Wang T, Guo F, et al.Xiaoerfupi alleviates the symptoms of functional dyspepsia by regulating the HTR3A and c-FOS. Biomed Pharmacother 2019;120:109442.

[[39]] Tian JS, Peng GJ, Wu YF, et al.A GC-MS urinary quantitative metabolomics analysis in depressed patients treated with TCM formula of xiaoyaosan. J Chromatogr B Analyt Technol Biomed Life Sci 2016;1026:227-235.

[[40]] Zhu X, Xia O, Han W, et al.Xiao Yao San improves depressivelike behavior in rats through modulation of b-arrestin 2-mediated pathways in hippocampus. Evid Based Complement Alternat Med 2014;2014:902516.

[[41]] Shepherd SO, Cocks M, Tipton KD, et al.Sprint interval and traditional endurance training increase net intramuscular triglyceridebreakdown and expression of perilipin 2 and 5. J Physiol 2013;591(3):657-675.

[[42]] Conte M, Franceschi C, Sandri M, et al.Perilipin 2 and age-related metabolic diseases: a new perspective. Trends Endocrinol Metab 2016;27(12):893-903.

[[43]] McManaman JL, Bales ES, Orlicky DJ, et al. Perilipin-2-null mice are protected against diet-induced obesity, adipose inflammation, and fatty liver disease. J Lipid Res 2013;54(5):1346-1359.

[[44]] Pawella LM, Hashani M, Eiteneuer E, et al.Perilipin discerns chronic from acute hepatocellular steatosis. J Hepatol 2014;60(3):633-642.

[[45]] Pennington K, Föcking M, McManus CA, et al. A proteomic investigation of similarities between conventional and herbal antidepressant treatments. J Psychopharmacol 2009;23(5): 520-530.

RIGHTS & PERMISSIONS

2022 Acupuncture and Herbal Medicine